Replimune Group Inc (REPL) Directors and Executive Officers

Officers & Directors

PAOLO PUCCI
Director

EMILY HILL
Chief Financial Officer (Principal Financial Officer)

PHILIP ASTLEY-SPARKE
Director

JOSEPH SLATTERY
Director

SUSHIL PATEL
Chief Executive Officer and Director (Principal Executive Officer)

ROBERT COFFIN
Director

ANDREW SCHWENDENMAN
Chief Accounting Officer (Principal Accounting Officer)

CHRISTY OLIGER
Director

DIETER WEINAND
Director

VELEKA PEEPLES-DYER
Director

KAPIL DHINGRA
Director

HYAM LEVITSKY
Director,

Replimune Group Inc currently has 465 employees.

News about Replimune Group Inc Key Personnel

Replimune Group Inc Gains FDA Alignment for RP1 Accelerated Approval Pathway, Inspiring 11.54% Share Price Surge in Q3 2024,

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
- Alignment with FDA on accelerated approval pathway for RP1 in anti-PD1 failed melanoma
- Share price increases by 11.54% in Q3 of 2024
- Cumulative net loss of $-220 million with a negative return on assets
- Ranking improves to 3241 in overall ROA ranking
Replimune Group Inc, a prominent player in the field of oncolytic immunotherapies, recently disclosed positive developments regarding their accelerated approval pathway for RP1 in anti-PD1 failed melanoma. The company had a successful Pre-BLA (Biologics License Application) meeting with the Food and Drug Administration (FDA), solidif...

Replimune Appoints New CEO and Strengthens Executive Team as Shares Surge

Replimune Announces Leadership Transitions and Strengthened Executive Team as Shares Trade Higher
Replimune Group Inc, a renowned biotechnology company specializing in oncolytic immunotherapies, has recently announced significant leadership transitions and the appointment of Sushil Patel as CEO. The company s former CEO, Philip Astley-Sparke, will now assume the role of Executive Chairman. This move aims to enhance Replimune s growth strategy and support its mission to revolutionize cancer treatment.
In addition to the management shakeup, Replimune also revealed its financial performance for the past year. The company recorded a cumulative net loss of $-210 million during the twelve months ending in...